In severe COVID‐19 cases, a study showed CP therapy was well tolerated and could improve the clinical outcomes by neutralizing viremia.[14] Another study showed that in patients with severe or life‐threatening COVID‐19, convalescent plasma therapy added to standard treatment, compared with standard treatment alone, there was no significant statistical improvement in time to clinical improvement within 28 days.[30]. This evidence concerns the gene CP and COVID-19.